FDA states It may be reasonable to first establish efficacy in older adults who may be at greater risk of harm due to muscle loss, but the development should be expanded to younger patients with obesi

ir_statement / Aug 8, 2026 / receipt

potential for disruptions at the FDA or other government agencies to negatively affect our business

ir_statement / Aug 8, 2026 / receipt

the ability of the Company to obtain sufficient financing on acceptable terms when needed to fund development and operations

ir_statement / Aug 8, 2026 / receipt

the ability to fund planned clinical development as well as other operations of the Company

ir_statement / Aug 8, 2026 / receipt

the Company’s ability to reach agreement with FDA on study design requirements for the Company’s planned clinical studies, including for the planned PLATEAU Phase 2b study for enobosarm and the cost t

ir_statement / Aug 8, 2026 / receipt

the expected costs, timing, patient population, design, endpoints and results of the planned PLATEAU Phase 2b study or any future Phase 3 studies of enobosarm in patients with obesity

ir_statement / Aug 8, 2026 / receipt

whether the Company will be able to raise sufficient capital, dilutive or otherwise, to fund the PLATEAU Phase 2b study of enobosarm in patients with obesity or any other studies

ir_statement / Aug 8, 2026 / receipt

after deducting the underwriting discounts and commissions and estimated costs payable by the Company

ir_statement / Aug 8, 2026 / receipt

Veru received net proceeds from an underwritten public offering of approximately $23.4 million

ir_statement / Aug 8, 2026 / receipt